Findings from this study suggest that the inhibitor specifically targets KDM4B in late S-phase due to activation of PLK1 transcription via B-MYB, justifying the development of this KDM4B inhibitor for AR+ prostate cancer and opening up the possibility for new treatments in the AR+ subgroup of BC (93). Here, AR is linked to prostate carcinoma.